ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 002

Re-analysis of the APPLE (Atherosclerosis Prevention in Paediatric Lupus Erythematosus) Trial Identifies Novel Determinants of Patient Heterogeneity and a Distinct Lipid Metabolomic Signature of Atherosclerosis Progression

Coziana Ciurtin1, Junjie Peng1, Pierre Donnes1, Stacy Ardoin2, Laura Schanberg3, Laura Lewandowski4, George A Robinson1 and Elizabeth Jury1, 1University College London, London, United Kingdom, 2Nationwide Children's Hospital, Columbus, OH, 3Duke University Medical Center, Durham, NC, 4NIAMS, NIH, Bethesda, MD

Meeting: 2023 Pediatric Rheumatology Symposium

Keywords: Bioinformatics, Cardiovascular, Carotid Artery Disease, metabolomics, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Thursday, March 30, 2023

Title: Plenary Abstracts Session I

Session Type: Plenary Session

Session Time: 2:30PM-3:30PM

Background/Purpose: Juvenile-onset systemic lupus erythematosus (JSLE) is associated with chronic inflammation and increased risk of atherosclerosis. The APPLE trial was a randomised, placebo-controlled trial of atorvastatin for atherosclerosis progression in JSLE, using carotid intima-media thickness (CIMT) measurements as primary outcome.

Methods: Unsupervised clustering analysis was used to stratify JSLE patients by their baseline CIMT and identify patterns of CIMT progression over 36 months. An additional in-depth metabolomic analysis was performed to identify lipidomic signatures predictive of CIMT progression. Correlation and univariate regression analyses explored associations between patient and disease characteristics and serum biomarkers. Machine learning techniques and ROC analyses were used to identify and validate a serum metabolomic signature of high CIMT progression.

Results: Baseline CIMT measurements stratified 151 JSLE patients recruited to the APPLE trial into three groups with distinct CIMT progression trajectories irrespective of the treatment allocation (Figure). Two distinct CIMT progression rates (high vs. low), characterised by higher total and low-density lipoprotein (LDL) cholesterol levels (P=0.001 and P=0.002, respectively) were found in the placebo group, while patients treated with atorvastatin had three distinct CIMT trajectories (high, intermediate and low progression), not associated with any relevant biomarkers. A robust metabolomic signature predictive of high CIMT progression in the placebo arm was identified (AUC = 80.7%).

Conclusion: This complementary analysis of the APPLE trial provides new evidence for the significant heterogeneity of subclinical atherosclerosis in JSLE and its distinct progression trajectories irrespective of treatment allocation. Clinical trial patient stratification using the newly identified metabolomic signature predictive of increased natural atherosclerosis progression rate may improve results. Despite being effective in lowering serum lipids, atorvastatin did not prevent the CIMT progression in many at risk JSLE patients, highlighting the need for personalised therapies to address various molecular mechanism driving atherosclerosis in JSLE.

Supporting image 1Figure 1: JSLE stratification (all APPLE patients with complete baseline data, N&#3f151) by baseline CIMT (12 measures). A) Baseline CIMT measures of patients with juvenile-onset SLE were stratified using unsupervised hierarchical clustering. All 12 CIMT measures were standardised within each row by Z score and plotted as a heat map, representing the relationship to the mean of the group (red represents relatively high CIMT measures and blue represents relatively low CIMT measures). Each column represents a patient with JSLE. Three groups of patients with distinct baseline CIMT profiles were identified. B-C) Box and whisker plots show baseline and 36-month MMeanIMT measurements (APPLE primary outcome) in the identified high, intermediate and low baseline CIMT groups. Comparisons between groups were performed using Wilcoxon signed-rank test (* p < 0.05; ** p < 0.01; *** p < 0.001). D) Distinct longitudinal MMeanIMT progression from baseline to 36 months of the high, intermediate and low CIMT progression groups (Mean, 95% CI), irrespective of treatment allocation. (Only JSLE patients with completed CIMT data at 36 months were included in the panel C-D, N&#3f121). Legend: CIMT- carotid intima-media thickness; MMeanIMT - Mean-Mean IMT common carotid artery measurement.


Disclosures: C. Ciurtin: GlaxoSmithKlein(GSK), 5, UCB, 6; J. Peng: None; P. Donnes: GlaxoSmithKlein(GSK), 5; S. Ardoin: None; L. Schanberg: Bristol-Myers Squibb(BMS), 5, Sanofi, 12, DSMB member, UCB, 12, DSMB chair; L. Lewandowski: None; G. Robinson: None; E. Jury: GlaxoSmithKlein(GSK), 5.

To cite this abstract in AMA style:

Ciurtin C, Peng J, Donnes P, Ardoin S, Schanberg L, Lewandowski L, Robinson G, Jury E. Re-analysis of the APPLE (Atherosclerosis Prevention in Paediatric Lupus Erythematosus) Trial Identifies Novel Determinants of Patient Heterogeneity and a Distinct Lipid Metabolomic Signature of Atherosclerosis Progression [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 4). https://acrabstracts.org/abstract/re-analysis-of-the-apple-atherosclerosis-prevention-in-paediatric-lupus-erythematosus-trial-identifies-novel-determinants-of-patient-heterogeneity-and-a-distinct-lipid-metabolomic-signature-of-ather/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2023 Pediatric Rheumatology Symposium

ACR Meeting Abstracts - https://acrabstracts.org/abstract/re-analysis-of-the-apple-atherosclerosis-prevention-in-paediatric-lupus-erythematosus-trial-identifies-novel-determinants-of-patient-heterogeneity-and-a-distinct-lipid-metabolomic-signature-of-ather/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology